Zhengye Biotechnology Holding Limited · NASDAQ:ZYBT
Zhengye Biotechnology — IPO Roadshow (June 2024)
30 slides from Zhengye Biotechnology's IPO roadshow presentation, Jun 21, 2024
Slide 1: Zhengye Biotechnology Holding Limited Investor Presentation
Zhengye Biotechnology Holding Limited Investor Presentation Issuer Free Writing Prospectus dated June 20, 2024 Filed Pursuant to Rule 433 of the Securities Act of 1933, as amended Relating to Preliminary Prospectus dated June 14, 2024 Registration Statement No. 333 - 276436 Proposed Nasdaq Ticker: Z
Slide 2: Free Writing Prospectus Statement
Free Writing Prospectus Statement This free writing prospectus relates to the proposed public offering of ordinary shares (“Ordinary Shares”) of Zhengye Biotechnology Holding Limited (“we”, “us”, or “our”) and should be read together with the Registration Statement we filed with the U . S . Securiti
Slide 3: Forward-Looking Statement
Forward - Looking Statement This presentation contains forward - looking statements that reflect our current expectations and views of future events, all of which are subject to risks and uncertainties . Forward - looking statements give our current expectations or forecasts of future events . You c
Slide 4: Offering Summary
Offering Summary Zhengye Biotechnology Holding Limited Issuer Nasdaq Capital Market: ZYBT Exchange/Ticker Ordinary Shares Securities Offered 45,666,376 Ordinary Shares Pre - Offering Shares Outstanding 1,250,000 Ordinary Shares Number of Shares Offered 46,916,376 Ordinary Shares Post - Offering Shar
Slide 5: Investment Highlights
Investment Highlights 1 2 3 4 5 High Production Quality and Quality Control 44 Diversified Products Extensive Distribution Channels Strong Research and Development Capabilities Experienced Management Team 5 See offering documents for further risks and disclosures. There is no guarantee that any spec
Slide 6: Content
Content Company and Business Overview 01 I ndustry Overview Growth Strategies Financial Highlights 02 03 04
Slide 7: Company Overview
Company Overview We focus on the research , development , manufacturing, and sales of veterinary vaccines , with an emphasis on vaccines for livestock. We market a diverse range of vaccines , including vaccines for swine , cattle , goats , sheep , poultry , and dogs . veterinary vaccines in our prod
Slide 8: Company Overview
Company Overview Our mission is to become a world - leading manufacturer and distributor of veterinary vaccines See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved. I nve stments may be speculative, illiquid and there is a risk o
Slide 9: The Production Process
The Production Process See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved. I nve stments may be speculative, illiquid and there is a risk of loss 9 • Sales department receives orders • Purchasing department purchase raw material
Slide 10: Corporate Structure
Corporate Structure TLjinmao Limited (BVI) Visuccess Holding Limited (Hong Kong) Zhengye Biotechnology Holding Limited (Cayman) VVAX Skyline Holdings Limited (BVI) Peg Biotechnology (HK) Holding Limited (Hong Kong) Hainan Senhan Biotechnology Co., Ltd. (PRC) Jilin Zhengye Biological Products Co., Lt
Slide 11: Strong R&D Capabilities – Independent R&D
Strong R&D Capabilities – Independent R&D • Have 49 experienced experts (+10 years experience) work for our R&D department with glory achievements and awards. • Own 1 research center, which collectively has helped the operating entity develop dozens of vaccines, inventions, and utility models. • Dev
Slide 12: Strong R&D Capabilities - Cooperative R&D
Strong R&D Capabilities - Cooperative R&D • Maintained long - term cooperative relationships with universities and institutions: - Universities and research institutes - early - stage basic research - Our R&D - basic research , pilot study and industrialization research 12 • Licensed to use vaccine
Slide 13: New Product Development Process
New Product Development Process Steps highlighted in yellow are subject to government/regulatory approval. 13 Lab investigation Pilot Production C linical Trial Application Clinical Trial Application for Registration of New Veterinary Drugs Conformity Inspection Certification of New Veterinary Drugs
Slide 14: Diversified Products – Commercialized Products
Diversified Products – Commercialized Products Products Portfolio 44 Veterinary Vaccines 14 See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved. I nve stments may be speculative, illiquid and there is a risk of loss 19 Swine vacc
Slide 15: Diversified Products – Commercialized Products
Diversified Products – Commercialized Products Products Portfolio 44 Veterinary Vaccines 15 See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved. I nve stments may be speculative, illiquid and there is a risk of loss
Slide 16: Diversified Products – Products in Pipeline
Diversified Products – Products in Pipeline Products 16 See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved. I nve stments may be speculative, illiquid and there is a risk of loss Collaborator Clinical Trial Status Status Type of
Slide 17: High Production Quality - By GMP & ISO
High Production Quality - By GMP & ISO R aw Materials and Viral Seeds Inspection Work in Process Check Product Examination The Whole Process of Manufacturing 17 Quality Control Management System Examinations Physical property inspection Sterility testing Safety testing Efficacy testing • the appeara
Slide 18: Extensive Distribution Channels
75.4% 23.4% 1.2% Extensive Distribution Channels • Domestic distributors cover 29 provincial - level administrative regions of China • International distributors cover Vietnam, Pakistan, and Egypt • 212* distributor s globally • The authority arranges one or two tenders each year • We are participat
Slide 19: Experienced Management Team
Experienced Management Team 19 Songlin Song Chief Executive Officer Veterinarian Professionals with more than 20 years of industry experience • Chief Executive Officer since May 2023 . • Director and General Manager of our operating entity since September 2018 . • General Manager of China Animal Hus
Slide 20: Experienced Management Team
Experienced Management Team 20 See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved. I nve stments may be speculative, illiquid and there is a risk of loss Yuyou He • Vice General Manager since May 2023 . • Deputy General Manager
Slide 21: Content
Content Company and Business Overview 01 I ndustry Overview Growth Strategies Financial Highlights 02 03 04
Slide 22: Industry Overview
Industry Overview 1.6 2.2 2.5 2.5 2.7 2.9 3.0 3.2 2019 2020 2021 2022 2023E 2024E 2025E 2026E Ranking of Revenue of China’s Veterinary Vaccine Companies (2) CAGR Period 16.0% 2019 - 2022 6.5% 2022 - 2026E US$ Billion Source: (1) China Veterinary Drug Association, Literature Review, and Frost & Sulli
Slide 23: Industry Overview
Industry Overview See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved. I nve stments may be speculative, illiquid and there is a risk of loss Source: China Veterinary Drug Association, Literature Review, and Frost & Sullivan Anal
Slide 24: Industry Overview
Industry Overview 0.20 0.25 0.30 0.29 0.33 0.36 0.38 0.39 2019 2020 2021 2022 2023E 2024E 2025E 2026E CAGR Period 13.2% 2019 - 2022 7.8% 2022 - 2026E US$ Billion Source: China Veterinary Drug Association, Literature Review, and Frost & Sullivan Analysis *Note: This vaccine market includes vaccines f
Slide 25: Content
Content Company and Business Overview 01 I ndustry Overview Growth Strategies Financial Highlights 02 03 04
Slide 26: Growth Strategies
Growth Strategies 26 01 02 03 04 05 Develop high - demand products and expand business by entering pet vaccines industry Expand sales and distribution network • Continue to increase sales to existing customers and focus on developing new markets and new customers • E ntry into S outheast Asia market
Slide 27: Content
Content Company and Business Overview 01 I ndustry Overview Growth Strategies Financial Highlights 02 03 04
Slide 28: Financial Highlights
Financial Highlights $36.7 $29.8 FY2022 FY2023 Revenue 90.5% 6.3% 3.2% Revenue Breakdown by Products 89.3% 7.3% 3.4% FY2022 FY2023 US$ Million 28 Swine vaccines Poultry vaccines Other vaccines See offering documents for further risks and disclosures. There is no guarantee that any specific outcome w
Slide 29: Financial Highlights
Financial Highlights Net Income $21.6 $18.3 FY2022 FY2023 Gross Profit and Gross Profit Margin US$ Million Gross profit margin 59.0% 61.4% 29 $7.8 $5.3 FY2022 FY2023 US$ Million See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved
Slide 30: Contact
Contact 30 Issuer: Email: ir@jlzybio.com Tel: +86 - 0432 - 63047008 Address: No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin City, Jilin Province, China Zhengye Biotechnology Holding Limited Underwriter: Email: info@kingswoodus.com Tel: +1 - 800 - 535 - 6981 Address: Tower 56,
Zhengye Biotechnology Holding — IPO Roadshow (June 2024) on 6ix